Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Further registration is expected next year. Targeted therapy proved to prolong time to disease progression of renal cell cancer. If administered sequentially they prolong overall survival as well. The treatment usually tends to last. The disease gains status of chronic illness. Molecular predictive factors are not available and decisions regarding specific therapeutic choices are based on clinical factors. Due to all aforementioned the toxicity profile and related quality of life should be of special interest. The article is the discussion of methodology of quality of life clinical trials, the data collection, data analysis and review of current knowledge regarding this issue in context of treatment of renal cell carcinoma based on molecularly targeted therapy.
Authors and Affiliations
Jakub Żołnierek, Piotr Wysocki
Keywords
Related Articles
- EP ID EP53129
- DOI -
- Views 239
- Downloads 0
Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen.
Central venous catheters and complications in cancer patients
Vascular access has great importance in the treatment of patients submitted to prolonged chemotherapy. We report two patients with early and late complications related to the presence of a central venous catheter. The fi...
Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT)...
Late relapse of chronic myeloid leukemia after allogeneic stem cell tranplan
Chronic myeloid leukemia now is a disease which in the most cases is well manageable with tyrosine kinase inhibitors treatment. Still however the only potentially curable therapeutic approach is for chronic myeloid leuke...
Zespół rozpadu guza
Zespół rozpadu guza jest stanem zagrożenia życia występującym u pacjentów z rozległymi nowotworami, u których pod wpływem chemioterapii bądź samoistnie dochodzi do masywnego rozpadu komórek nowotworowych z uwolnieniem ic...